reviewed april 2026|next review october 2026|88 physicians psi has verified|539888 published studies
Thymopoietin
Thymopoietin is a 49-amino-acid thymic polypeptide whose active pentapeptide fragment thymopentin (TP-5) was tested in clinical trials for HIV-related immunodeficiency, rheumatoid arthritis, and primary immunodeficiency, with regulatory approval in several countries.
Evidence landscape: 539888 published studies
539,888 published items (broad thymus/immune query). 35 human studies and 133 animal studies.
- 35 Human
- 133 Animal
- 32 Reviews
- 539688 Other research
Not FDA-approved in the United States. Thymopentin (TP-5) has been approved in several countries outside the US for immune modulation. The clinical trial data predates modern immunology methodology.
Not available as a medication in the United States. Thymopentin is available as an injectable in some Asian and European markets. Thymopoietin itself is not sold as a therapeutic product.
Thymopoietin is a naturally occurring (the body's own) 49-amino-acid polypeptide produced by thymic epithelial cells. The active fragment thymopentin (TP-5, residues 32-36: Arg-Lys-Asp-Val-Tyr) retains the immunomodulatory activity. Distinct from thymosin alpha-1 and thymulin.
PSI Assessment
The thymus gland does not simply house immune cells. It actively instructs them through peptide signals, and thymopoietin is one of the most studied of these signals. Goldstein's laboratory isolated this 49-amino-acid polypeptide in 1979, and subsequent work identified that just five amino acids (residues 32-36, the fragment called thymopentin or TP-5) retain the full immunomodulatory activity. Thymopentin was tested in clinical trials for HIV-related immunodeficiency, rheumatoid arthritis, and primary immunodeficiency, with regulatory approval in several countries. The connection to myasthenia gravis research revealed that thymopoietin also affects the neuromuscular junction. The clinical data predates modern immunology methods, and whether thymopentin would meet current Western trial standards is an open question.
Active fragment thymopentin (TP-5) tested in clinical trials for HIV and autoimmune disease. Regulatory approval in several countries. Established that the thymus actively directs T-cell development through peptide signals.
Thymopoietin is a 49-amino-acid polypeptide produced by thymic epithelial cells. The active pentapeptide fragment thymopentin (TP-5, residues 32-36: Arg-Lys-Asp-Val-Tyr) retains the immunomodulatory activity. TP-5 induces T-cell differentiation markers (CD2, CD4, CD8) on precursor cells and enhances IL-2 production. The connection between thymopoietin and myasthenia gravis research revealed that it also modulates acetylcholine receptor expression at the neuromuscular junction, linking thymic biology to neuromuscular function.
What the evidence supports
Thymopoietin induces T-cell differentiation markers on precursor cells. The active pentapeptide fragment thymopentin (TP-5) was tested in controlled clinical trials for immunodeficiency and autoimmune conditions. Regulatory approval in several countries provides clinical validation. The thymus produces specific peptide signals that direct T-cell development.
What is not yet established
Whether thymopentin produces clinically meaningful immune restoration by current Western trial standards. The clinical trial data predates modern immunology methodology. Comparative efficacy against thymosin alpha-1 or other immune modulators. Long-term outcomes data.
Research Evidence
The findings below cover thymopoietin's role in T-cell development, the thymopentin clinical trial history, and the neuromuscular junction connection.
Evidence by condition
Evidence dimensions available for each condition Thymopoietin has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Immunodeficiency | ||||
| T-Cell Development | ||||
| Rheumatoid Arthritis | ||||
| Neuromuscular Function |
Thymopentin (TP-5) was tested in controlled clinical trials for immunodeficiency and autoimmune conditions, including HIV-related immune decline and rheumatoid arthritis. Regulatory approval was granted in several countries.
The clinical trial data predates modern immunology methodology. Whether thymopentin would meet current Western randomized controlled trial standards has not been tested.
35 Human|133 Animal|32 Reviews
View all 539888 indexed studiesHow Thymopoietin Works
Thymopoietin is a naturally occurring (the body's own) 49-amino-acid polypeptide from thymic epithelial cells. The active fragment thymopentin (TP-5) promotes T-cell differentiation by inducing expression of CD2, CD4, and CD8 markers on precursor cells. It also modulates acetylcholine receptor expression at the neuromuscular junction.
The thymus gland is the training camp for immune cells. Thymopoietin trains T cells to become effective defenders. As the thymus shrinks with age, less thymopoietin is produced, and immune training weakens.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
49-amino acid polypeptide from thymic epithelial cells. Active fragment thymopentin (TP-5, residues 32-36) promotes T cell differentiation, enhances IL-2 production, and modulates CD4/CD8 ratios.
What is Thymopoietin being studied for?
Researchers are studying Thymopoietin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Thymopoietin overall. This means a compound can have human studies for one condition but only animal data for another.
Immunodeficiency
·Human TrialsThymopentin (TP-5) was tested in clinical trials for HIV-related immunodeficiency and primary immunodeficiency. Regulatory approval in several countries provides clinical validation of immunomodulatory effects.
Limitations: The clinical data predates modern immunology methodology. Whether thymopentin produces clinically meaningful immune restoration by current Western trial standards has not been established.
T-Cell Development
·Animal StudiesThymopoietin and thymopentin induce T-cell differentiation markers on precursor cells. The mechanism of T-cell instruction by thymic peptide signals is well-characterized.
Limitations: The in vitro T-cell differentiation effects are reproducible. Translation to clinical immune reconstitution is less certain.
Rheumatoid Arthritis
·Animal StudiesThymopentin was tested in clinical trials for rheumatoid arthritis with reported immune-modulating effects.
Limitations: The trial data is dated and has not been replicated to modern standards. Comparative efficacy against current rheumatoid arthritis biologics is unknown.
Neuromuscular Function
·PreclinicalThymopoietin modulates acetylcholine receptor expression at the neuromuscular junction. This connection was discovered through myasthenia gravis research.
Limitations: The neuromuscular effects are primarily characterized in laboratory models. No therapeutic application for neuromuscular conditions has been developed.
Safety and Regulatory Status
FDA Status: Not FDA-approved in the United States. Thymopentin (TP-5) has regulatory approval in several countries outside the US.
Availability: Not available as a medication in the United States. Available as thymopentin in some Asian and European markets.
Class context: Thymopoietin is a naturally occurring (the body's own) thymic hormone. Thymopentin has a documented clinical safety profile from trials and post-marketing use in approved markets.
Thymopoietin is a naturally occurring (the body's own) thymic hormone. Thymopentin (TP-5) has been used clinically in several countries with an acceptable safety profile documented in published trials.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Thymopoietin discussion.
Comparison and Related Research
Thymopoietin is one of several thymic factors studied for immune modulation. The comparisons below clarify its position relative to other thymic peptides.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The paper that reported the isolation and complete amino acid sequence of thymopoietin from bovine thymus. This 49-amino-acid polypeptide was shown to induce T-cell differentiation markers, establishing thymopoietin as a distinct thymic hormone separate from other thymic factors.Goldstein G, 1975 in Ann N Y Acad Sci. View on PubMed
- 2.A pharmacokinetic study of thymopentin (TP-5), the active pentapeptide fragment (residues 32-36) of thymopoietin, in human plasma. The study found a very short half-life, which informed subsequent work on dosing strategies and analog development for clinical applications.Tischio JP, 1979 in Int J Pept Protein Res. View on PubMed
- 3.A double-blind, placebo-controlled trial evaluating thymopentin as an immunomodulatory adjunct in asymptomatic HIV-positive patients on AZT. The trial assessed whether thymopentin could slow CD4 decline and delay disease progression in early HIV infection.Goldstein G et al., 1995 in J Acquir Immune Defic Syndr Hum Retrovirol. View on PubMed
- 4.A clinical review of thymopentin use in managing viral infections including herpes and hepatitis. The paper summarized evidence that thymopentin administration enhanced T-cell-mediated immune responses and reduced recurrence rates in certain chronic viral conditions.Sundal E et al., 1994 in Arzneimittelforschung. View on PubMed
- 5.An analysis of prognostic factors from a double-blind thymopentin trial in HIV patients. The study evaluated serum viral load, drug resistance mutations, and CD4 counts as predictors of disease progression, contributing to the understanding of thymopentin's immunomodulatory role in HIV management.Merigan TC et al., 1996 in AIDS. View on PubMed
- 6.A clinical study of thymopentin as prophylactic treatment in patients experiencing recurrent respiratory tract infections. The results suggested a reduction in infection frequency and improved immune parameters in the treated group.Sundal E et al., 1993 in Br J Clin Pract. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.